This observation, if applicable to spontaneous lupus is likely to have important implications for the treatment of active SLE: an agent such as an Ezh2 inhibitor that blocks both B and T cell differentiation, might be particularly efficacious for the treatment of SLE and other autoimmune disorders. The gene discussed is EZH2; the disease is systemic lupus erythematosus.